GE HealthCare is currently conducting clinical trials to evaluate the efficacy and safety of mangaciclanol, an MRI contrast agent.

We are not currently providing access to mangaciclanol outside of these clinical trials. At this time we believe that participation in a clinical trial is the optimal way to access mangaciclanol, as it allows us to gather the necessary data to support regulatory approvals and ensure the best outcomes for patients.

This policy is subject to change and may be revised by GE HealthCare in the future.